Free shipping on all orders over $ 500

Canagliflozin

Cat. No. M2002

All AbMole products are for research use only, cannot be used for human consumption.

Canagliflozin Structure
Synonym:

JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
2mg USD 32  USD32 In stock
5mg USD 48  USD48 In stock
10mg USD 64  USD64 In stock
50mg USD 94  USD94 In stock
100mg USD 120  USD120 In stock
200mg USD 174  USD174 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2) for CHO-hSGLT2, CHO-rSGLT2 and CHO-mSGLT2 with IC50 of 4.4 nM, 3.7 nM and 2 nM, which is responsible for at least 90% of the glucose reabsorption in the kidney. Canagliflozin increased LDL cholesterol, urinary tract infections, genital mycotic infections, and was associated increased urination and episodes of hypotension and hypoglycemia. Canagliflozin shows pronounced anti-hyperglycemic effects in high-fat diet fed KK (HF-KK) mice. Oral administration at 30 mg/kg of Canagliflozin to male SD rats induces glucose excretion over 24 hours by 3,696 mg per 200 g body weight. Dose dependently, canagliflozin decreased calculated 24-h mean RT(G) with maximal reduction to approximately 60 mg/dl, and increased mean 24-h UGE. At doses >200 mg administered before breakfast, canagliflozin reduced postprandial PG and serum insulin excursions at that meal. Canagliflozin was generally well tolerated. Canagliflozin has entered in a Phase III clinical trial for the treatment of diabetes mellitus and type 2 renal insufficiency.

Chemical Information
Molecular Weight 444.52
Formula C24H25FO5S
CAS Number 842133-18-0
Solubility (25°C) DMSO ≥ 50 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Liang Y, et al. PLoS One. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.

[2] Sha S, et al. Diabetes Obes Metab. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.

[3] Nomura S, et al. J Med Chem. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

Related SGLT Products
Velagliflozin 

Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.

Tianagliflozin

Tianagliflozin is an SGLT2 inhibitor that may be used in studies related to type 2 diabetes.

JTT-662

JTT-662 is an SGLT1 inhibitor that can be used in studies related to type 2 diabetes.

JP-2266

JP-2266 is a dual SGLT1/2 inhibitor that can be used in studies related to diabetes.

Tofogliflozin

Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.

  Catalog
Abmole Inhibitor Catalog




Keywords: Canagliflozin, JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284 supplier, SGLT, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.